BeOne Medicines (ONC) Competitors $250.30 -3.09 (-1.22%) As of 07/11/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ONC vs. GSK, TAK, ARGX, BNTX, TEVA, INSM, SMMT, ITCI, GMAB, and RDYShould you be buying BeOne Medicines stock or one of its competitors? The main competitors of BeOne Medicines include GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Insmed (INSM), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. BeOne Medicines vs. Its Competitors GSK Takeda Pharmaceutical argenex BioNTech Teva Pharmaceutical Industries Insmed Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories BeOne Medicines (NASDAQ:ONC) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability. Which has preferable valuation & earnings, ONC or GSK? GSK has higher revenue and earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeOne Medicines$3.81B7.20-$644.79M-$3.72-67.28GSK$40.10B1.96$3.29B$1.9419.74 Do analysts prefer ONC or GSK? BeOne Medicines presently has a consensus target price of $320.67, suggesting a potential upside of 28.11%. GSK has a consensus target price of $37.38, suggesting a potential downside of 2.39%. Given BeOne Medicines' stronger consensus rating and higher possible upside, analysts clearly believe BeOne Medicines is more favorable than GSK.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeOne Medicines 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00GSK 1 Sell rating(s) 7 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.11 Does the media refer more to ONC or GSK? In the previous week, GSK had 2 more articles in the media than BeOne Medicines. MarketBeat recorded 16 mentions for GSK and 14 mentions for BeOne Medicines. GSK's average media sentiment score of 0.85 beat BeOne Medicines' score of 0.36 indicating that GSK is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral GSK 10 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, ONC or GSK? BeOne Medicines has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Do institutionals and insiders believe in ONC or GSK? 48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 6.6% of BeOne Medicines shares are held by insiders. Comparatively, 10.0% of GSK shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is ONC or GSK more profitable? GSK has a net margin of 9.89% compared to BeOne Medicines' net margin of -9.40%. GSK's return on equity of 48.82% beat BeOne Medicines' return on equity.Company Net Margins Return on Equity Return on Assets BeOne Medicines-9.40% -7.55% -4.42% GSK 9.89%48.82%11.15% SummaryGSK beats BeOne Medicines on 12 of the 17 factors compared between the two stocks. Get BeOne Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONC vs. The Competition Export to ExcelMetricBeOne MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.43B$2.42B$5.54B$9.08BDividend YieldN/A1.81%5.06%4.03%P/E Ratio-67.289.2228.2820.33Price / Sales7.20648.96411.8596.42Price / CashN/A22.3426.2427.98Price / Book7.344.638.125.50Net Income-$644.79M$30.99M$3.19B$250.38M7 Day Performance3.86%6.64%3.68%2.19%1 Month Performance-7.17%22.22%7.69%10.92%1 Year PerformanceN/A-3.88%29.35%16.41% BeOne Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCBeOne Medicines3.4424 of 5 stars$250.30-1.2%$320.67+28.1%N/A$27.43B$3.81B-67.2811,000Trending NewsAnalyst DowngradeInsider TradeGSKGSK1.7948 of 5 stars$38.26-0.6%$37.38-2.3%-2.2%$78.17B$40.10B19.7268,629Gap DownTAKTakeda Pharmaceutical2.1183 of 5 stars$15.55+0.8%N/A+9.2%$48.81B$30.09B70.6949,281ARGXargenex4.429 of 5 stars$543.32-0.3%$728.06+34.0%+20.1%$33.18B$2.25B33.521,599Positive NewsBNTXBioNTech1.6378 of 5 stars$109.65+1.3%$137.86+25.7%+32.9%$26.44B$2.98B-32.256,772TEVATeva Pharmaceutical Industries4.1241 of 5 stars$17.05flat$24.13+41.5%-5.2%$19.51B$16.54B-14.8336,830Positive NewsINSMInsmed4.5405 of 5 stars$98.50+0.3%$106.80+8.4%+28.0%$18.55B$363.71M-16.551,271Positive NewsSMMTSummit Therapeutics2.871 of 5 stars$24.35+7.6%$34.67+42.4%+192.4%$18.23B$700K-71.60110High Trading VolumeITCIIntra-Cellular Therapies0.671 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560News CoverageGMABGenmab A/S3.9892 of 5 stars$20.41-0.1%$37.60+84.2%-20.9%$13.02B$3.12B11.602,682Positive NewsAnalyst UpgradeRDYDr. Reddy's Laboratories2.7584 of 5 stars$15.08+1.3%$16.95+12.4%-8.8%$12.59B$3.81B22.8527,811 Related Companies and Tools Related Companies GSK Alternatives TAK Alternatives ARGX Alternatives BNTX Alternatives TEVA Alternatives INSM Alternatives SMMT Alternatives ITCI Alternatives GMAB Alternatives RDY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONC) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeOne Medicines Ltd. - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BeOne Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.